ClinicalTrials.gg
CompletedNCT04578834APPLAUSE-IgANUpdated Nov 4, 2026Results posted

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

A Phase 3 interventional study of Placebo and LNP023 in IgA Nephropathy, sponsored by Novartis Pharmaceuticals. Completed at 177 sites in 35 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Updated Nov 4, 2026Results postedStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
517
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Glomerulonephritis, IGA by Novartis — 9 open to participants now, 12 under way, 7 of them phase 3. Glomerulonephritis, IGA · Novartis.

Enrollment
2nd of 14
517 · median 108
Started
2021
with 2 others
Phase 3
8 of 18
5 open now
Registered
3rd of 18
by date

Among the 18 studies in Glomerulonephritis, IGA by Novartis, this one is the 2nd largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2021, is one of 8 in phase 3, and was the 3rd registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

9 of the 18 studies in Glomerulonephritis, IGA by Novartis are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Glomerulonephritis, IGA by Novartis, or all of them as a file.
02

Study summary

The study was designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of iptacopan (LNP023) at a dose of 200 mg b.i.d. compared to placebo on top of maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease progression in primary IgA Nephropathy patients.

Read the detailed description

The purpose of the study was to evaluate the efficacy and safety of iptacopan (LNP023) compared to placebo on proteinuria reduction and slowing disease progression in primary IgAN patients. This study served as the pivotal trial supporting the registration of iptacopan in IgA Nephropathy patients with the aim to demonstrate a clinically meaningful reduction in in eGFR slope decline and reduction in proteinuria. The trial continued in a blinded fashion to confirm long-term efficacy based on annualized total slope of eGFR decline over 24 months to provide confirmatory evidence of LNP023 efficacy and safety in treating patients with IgAN. The trial planned to enroll approximately 470 participants; 430 biopsy-proven IgAN participants with eGFR ≥30 mL /min/1.73m2 (main study population) and up to approximately 40 participants with eGFR 20 to \<30 mL/min/1.73m2 (severe renal impairment (SRI) population).

03

Conditions studied

  • IgA Nephropathy

Keywords

  • LNP023
  • IgA nephropathy
  • IgAN, proteinuria
  • UPCR
  • eGFR
  • eGFR slope
  • kidney function decline
04

Who can participate

The criteria were revised on the registry on Nov 4, 2026. See what changed

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients ≥ 18 years of age with an level and -confirmed IgA nephropathy as follows:
  • For patients eGFR* ≥ 45ml/min/1.73m2, a qualifying biopsy performed within the last 5 years is required.
  • For patients with eGFR* 30 to \<45ml/min/1.73m2, a qualifying biopsy performed within 2 years with \< 50% tubulointerstitial fibrosis is required.
  • For patients with eGFR* 20 to \<30ml/min/1.73m2, a qualifying biopsy performed at any time.

In all cases, if a historical biopsy is not available, one may be performed during screening. *eGFR calculated using the CKD-EPI formula (or modified MDRD formula according to specific ethnic groups and local practice guidelines)

  • Proteinuria due to primary diagnosis of IgA nephropathy as assessed at screening by UPCR ≥1 g/g (113 mg/mmol) sampled from FMV or 24h urine collection, as well as at the completion of the run-in period by UPCR ≥1 g/g (113 mg/mmol) calculated as the (geometric) mean of two 24h urine collections obtained within 14 days of each other at baseline.
  • Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infection is required prior to the start of study treatment. If the patient has not been previously vaccinated, or if a booster is required, vaccine should be given according to local regulations at least 2 weeks prior to first study drug administration. If study treatment has to start earlier than 2 weeks post vaccination, prophylactic antibiotic treatment should be initiated.
  • If not previously vaccinated, vaccination against Haemophilus influenzae infections should be given, if available and according to local regulations, at least 2 weeks prior to first study drug administration.
  • All patients must have been on supportive care including stable dose regimen of ACEi or ARB at either the locally approved maximal daily dose or the maximally tolerated dose (per investigators' judgment) for approximately 90 days before first study drug administration. In addition, if patients are taking diuretics, other antihypertensive medication, or other background medication for IgAN, the doses should also be stabilized for approximately 90 days prior to the first dosing of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Any secondary IgAN as defined by the investigator; secondary IgAN can be associated with cirrhosis, celiac disease, (HIV) infection, dermatitis herpetiformis, seronegative arthritis, small-cell carcinoma, lymphoma, disseminated tuberculosis, bronchiolitis obliterans, and inflammatory bowel disease, familial mediterranean fever, etc.
  • Sitting office SBP >140 mmHg or DBP >90 mmHg at the randomization visit
  • Patients previously treated with or other immunomodulatory agents such as but not limited to cyclophosphamide, rituximab, infliximab, eculizumab, canakinumab, mycophenolate mofetil (MMF) or mycophenolate sodium (MPS), cyclosporine, tacrolimus, sirolimus, everolimus, or systemic exposure (>7.5 mg/d prednisone/prednisolone equivalent) within 90 days (or 180 days for rituximab) prior to first study drug administration. Participants previously or currently treated with oral budesonide. Participants treated with endothelin (receptor) antagonists within 90 days prior to first study drug administration.
  • Prior use of iptacopan (LNP023) or prior enrollment in any other LNP023 clinical trial where study drug was taken, including matching placebo
  • History of recurrent invasive infections caused by encapsulated organisms, such as meningococcus and pneumococcus.
  • Active systemic bacterial, viral (including COVID-19) or fungal infection within 14 days prior to study drug administration.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
517 participants (actual)

Study arms

  • Experimental
    LNP023 200mg b.i.d

    Drug: LNP023

  • Placebo comparator
    Placebo to LNP023 200mg b.i.d

    Drug: Placebo

Interventions

  • DrugPlacebo

    Placebo to LNP023 200mg b.i.d

  • DrugLNP023

    LNP023 200mg b.i.d

    Also known as: iptacopan

06

What researchers measure

Primary outcomes

  1. Ratio to Baseline in UPCR at 9 Months - Interim Analysis

    Evaluated at interim analysis - Ratio to baseline in Urine Protein to Creatinine Ratio (UPCR), sampled from 24h urine collection, at 9 months. Ratio being: UPCR at 9 months in g/g divided by UPCR at Baseline in g/g. Lower values correspond to better outcomes.

    Time frame: Baseline and 9 months

  2. Annualized Total eGFR Slope Estimated Over 24 Months - Final Analysis

    Evaluated at final analysis - Annualized total eGFR slope over 24 months, expressed as the rate of change in estimated glomerular filtration rate (eGFR). eGFR is a measure of kidney function and was calculated using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula. A negative slope indicates declining kidney function. A less negative slope indicates a slower decline in kidney function and therefore a more favorable outcome.

    Time frame: 24 months

Secondary outcomes

  1. Change From Baseline in eGFR at 9 Months - Interim Analysis

    Evaluated at interim analysis - Change from baseline in estimated glomerular filtration rate (eGFR) at 9 months

    Time frame: Baseline and 9 months

  2. Proportion of Participants Reaching Proteinuria < 1 g/g of UPCR 24h at 9 Months - Interim Analysis

    Evaluated at interim analysis - Proportion of participants reaching proteinuria \< 1 g/g of Urine Protein-To-Creatinine Ratio (UPCR) sampled from 24-hour urine collection at 9 months, without receiving Corticosteroids/Immunosuppressant (CS/IS) or other newly approved drugs or initiating new background therapy for treatment of IgAN or initiating Kidney Replacement Therapy (KRT). Marginal proportion can be interpreted as the population average probability of being a responder in each treatment group.

    Time frame: Baseline and 9 months

  3. Annualized Total eGFR Slope Estimated Over 12 Months - Interim Analysis

    Evaluated at interim analysis -Annualized total eGFR slope over 12 months, expressed as the rate of change in estimated glomerular filtration rate (eGFR). eGFR is a measure of kidney function. A negative slope indicates declining kidney function. A less negative slope indicates a slower decline in kidney function and therefore a more favorable outcome.

    Time frame: 12 months

  4. Change From Baseline in the FACIT-Fatigue Total Score to 9 Months - Interim Analysis

    Evaluated at interim analysis -Functional Assessment Of Chronic Illness Therapy (FACIT)-Fatigue scale (version 4), is a 13-item questionnaire that assesses patient-perceived tiredness, weakness and difficulty conducting activities due to fatigue. The purpose of FACIT-Fatigue in this study was to assess the experience and impact of fatigue on participants with IgAN. Score ranges from 0 to 52, with higher scores indicating less fatigue.

    Time frame: Baseline and 9 months

  5. Number of Participants With Adverse Events in the Main Study Population During the On-treatment Period - Interim Analysis

    Number of participants with treatment-emergent Adverse Events, including clinically significant abnormal safety laboratory parameters and vital signs during the on-treatment period. The on-treatment period lasts from the date of first administration of study treatment to 7 days after the date of the last actual administration of any study treatment

    Time frame: Up to 24 months

  6. Number of Participants With Adverse Events in the SRI Population During the On-treatment Period - Interim Analysis

    Number of participants with treatment-emergent Adverse Events, including clinically significant abnormal safety laboratory parameters and vital signs during the on-treatment period. The on-treatment period lasts from the date of first administration of study treatment to 7 days after the date of the last actual administration of any study treatment

    Time frame: Up to 24 months

  7. Ratio to Baseline in UPCR at 9 Months - Final Analysis

    Evaluated at final analysis - Ratio to baseline in Urine Protein to Creatinine Ratio (UPCR), sampled from 24h urine collection, at 9 months. Ratio being: UPCR at 9 months in g/g divided by UPCR at Baseline in g/g. Lower values correspond to better outcomes. In line with the testing strategy, this endpoint was not tested at the final analysis.

    Time frame: Baseline and 9 months

  8. Proportion of Participants Reaching Proteinuria < 1 g/g of UPCR 24h at 9 Months - Final Analysis

    Evaluated at final analysis - Proportion of participants reaching proteinuria \< 1 g/g of Urine Protein-To-Creatinine Ratio (UPCR) 24h at 9 months, without receiving Corticosteroids/Immunosuppressant (CS/IS) or other newly approved drugs or initiating new background therapy for treatment of IgAN or initiating Kidney Replacement Therapy (KRT). Marginal proportion can be interpreted as the population average probability of being a responder in each treatment group.

    Time frame: Baseline and 9 months

  9. Time to First Occurrence of Composite Kidney Failure Endpoint Event - Final Analysis

    Evaluated at final analysis - Time to first occurrence of composite kidney failure endpoint, defined as a sustained decline in the eGFR of at least 30% from baseline for at least 4 weeks, a sustained eGFR of less than 15 mL/min/1.73m2 for at least 4 weeks, initiation of maintenance dialysis (defined as dialysis for a period of ≥4 weeks) or death from kidney failure. For clarity: Please note that the number of patients with a composite kidney failure endpoint event is presented with statistical analysis of the time to composite kidney failure endpoint event.

    Time frame: Up to 24 months

  10. Change From Baseline in the FACIT-Fatigue Total Score to 9 Months - Final Analysis

    Functional Assessment Of Chronic Illness Therapy (FACIT)-Fatigue scale (version 4), is a 13-item questionnaire that assesses patient-perceived tiredness, weakness and difficulty conducting activities due to fatigue. The purpose of FACIT-Fatigue in this study was to assess the experience and impact of fatigue on participants with IgAN. Score ranges from 0 to 52, with higher scores indicating less fatigue.

    Time frame: Baseline and Month 9

  11. Number of Participants With Adverse Events in the Main Study Population During the On-treatment Period - Final Analysis

    Number of participants with treatment-emergent Adverse Events, including clinically significant abnormal safety laboratory parameters and vital signs during the on-treatment period. The on-treatment period lasts from the date of first administration of study treatment to 7 days after the date of the last actual administration of any study treatment

    Time frame: Up to 24 months

  12. Number of Participants With Adverse Events in the SRI Population During the On-treatment Period- Final Analysis

    Number of participants with treatment-emergent Adverse Events, including clinically significant abnormal safety laboratory parameters and vital signs during the on-treatment period. The on-treatment period lasts from the date of first administration of study treatment to 7 days after the date of the last actual administration of any study treatment

    Time frame: Up to 24 months

07

Results

Posted Nov 4, 2026

Participant flow

Participant flow — Overall Study
MilestoneLNP023 200mg b.i.dPlacebo
Started259258
Started - main study population238239
Completed study - main study population227212
Started - sri population2119
Completed study - sri population1918
Main population ia-fas125125
Main population ia-saf222221
Sri population ia-saf1314
Sri population saf2119
Main population fas238239
Main population saf238239
Completed246230
Not completed1328
Withdrew: Adverse event01
Withdrew: Lost to follow-up32
Withdrew: Physician decision14
Withdrew: Subject decision921

Outcome measures

PrimaryRatio to Baseline in UPCR at 9 Months - Interim Analysis

Evaluated at interim analysis - Ratio to baseline in Urine Protein to Creatinine Ratio (UPCR), sampled from 24h urine collection, at 9 months. Ratio being: UPCR at 9 months in g/g divided by UPCR at Baseline in g/g. Lower values correspond to better outcomes.

Time frame:
Baseline and 9 months
Reported as:
Geometric mean · ratio
Ratio to Baseline in UPCR at 9 Months - Interim Analysis
ratioLNP023 200mg b.i.dPlacebo
Ratio to Baseline in UPCR at 9 Months - Interim Analysis0.562 (0.491 to 0.642)0.910 (0.792 to 1.046)
Statistical analysis
  • LNP023 200mg b.i.d vs Placebo · Mixed Model of Repeated Measures · p = <0.0001 (1-sided p-value) · Geometric mean ratio: 0.617 · 95% CI 0.514 to 0.740
PrimaryAnnualized Total eGFR Slope Estimated Over 24 Months - Final Analysis

Evaluated at final analysis - Annualized total eGFR slope over 24 months, expressed as the rate of change in estimated glomerular filtration rate (eGFR). eGFR is a measure of kidney function and was calculated using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula. A negative slope indicates declining kidney function. A less negative slope indicates a slower decline in kidney function and therefore a more favorable outcome.

Time frame:
24 months
Reported as:
Least squares mean · mL/min/1.73m^2/year
Annualized Total eGFR Slope Estimated Over 24 Months - Final Analysis
mL/min/1.73m^2/yearLNP023 200mg b.i.dPlacebo
Annualized Total eGFR Slope Estimated Over 24 Months - Final Analysis-3.100 ± 0.357-6.117 ± 0.361
Statistical analysis
  • LNP023 200mg b.i.d vs Placebo · longitudinal mixed effects model · p = <0.0001 · Lsm of difference: 3.017 · 95% CI 2.021 to 4.013
SecondaryChange From Baseline in eGFR at 9 Months - Interim Analysis

Evaluated at interim analysis - Change from baseline in estimated glomerular filtration rate (eGFR) at 9 months

Time frame:
Baseline and 9 months
Reported as:
Mean · mL/min/1.73m^2
Change From Baseline in eGFR at 9 Months - Interim Analysis
mL/min/1.73m^2LNP023 200mg b.i.dPlacebo
Change From Baseline in eGFR at 9 Months - Interim Analysis-2.487 (-4.035 to -0.939)-5.507 (-7.083 to -3.932)
Statistical analysis
  • LNP023 200mg b.i.d vs Placebo · Mixed Models Analysis · p = 0.0026 (1-sided p-value) · Adjusted mean difference: 3.020 · 95% CI 0.903 to 5.137
SecondaryProportion of Participants Reaching Proteinuria < 1 g/g of UPCR 24h at 9 Months - Interim Analysis

Evaluated at interim analysis - Proportion of participants reaching proteinuria \< 1 g/g of Urine Protein-To-Creatinine Ratio (UPCR) sampled from 24-hour urine collection at 9 months, without receiving Corticosteroids/Immunosuppressant (CS/IS) or other newly approved drugs or initiating new background therapy for treatment of IgAN or initiating Kidney Replacement Therapy (KRT). Marginal proportion can be interpreted as the population average probability of being a responder in each treatment group.

Time frame:
Baseline and 9 months
Reported as:
Number · Marginal proportion of participants
Proportion of Participants Reaching Proteinuria < 1 g/g of UPCR 24h at 9 Months - Interim Analysis
Marginal proportion of participantsLNP023 200mg b.i.dPlacebo
Proportion of Participants Reaching Proteinuria < 1 g/g of UPCR 24h at 9 Months - Interim Analysis0.425 (0.345 to 0.505)0.219 (0.148 to 0.290)
Statistical analysis
  • LNP023 200mg b.i.d vs Placebo · Regression, Logistic · p = 0.0002 (1-sided p-value) · Odds ratio (or): 3.122 · 95% CI 1.684 to 5.787
  • LNP023 200mg b.i.d vs Placebo · Diff. in marginal proportion: 0.206 · 95% CI 0.099 to 0.313
SecondaryAnnualized Total eGFR Slope Estimated Over 12 Months - Interim Analysis

Evaluated at interim analysis -Annualized total eGFR slope over 12 months, expressed as the rate of change in estimated glomerular filtration rate (eGFR). eGFR is a measure of kidney function. A negative slope indicates declining kidney function. A less negative slope indicates a slower decline in kidney function and therefore a more favorable outcome.

Time frame:
12 months
Reported as:
Least squares mean · mL/min/1.73m^2/year
Annualized Total eGFR Slope Estimated Over 12 Months - Interim Analysis
mL/min/1.73m^2/yearLNP023 200mg b.i.dPlacebo
Annualized Total eGFR Slope Estimated Over 12 Months - Interim Analysis-4.341 ± 0.730-6.944 ± 0.733
Statistical analysis
  • LNP023 200mg b.i.d vs Placebo · Longitudinal mixed effects model · p = 0.006 (1-sided p-value) · Least-squares mean: 2.603 · 95% CI 0.573 to 4.634
SecondaryChange From Baseline in the FACIT-Fatigue Total Score to 9 Months - Interim Analysis

Evaluated at interim analysis -Functional Assessment Of Chronic Illness Therapy (FACIT)-Fatigue scale (version 4), is a 13-item questionnaire that assesses patient-perceived tiredness, weakness and difficulty conducting activities due to fatigue. The purpose of FACIT-Fatigue in this study was to assess the experience and impact of fatigue on participants with IgAN. Score ranges from 0 to 52, with higher scores indicating less fatigue.

Time frame:
Baseline and 9 months
Reported as:
Mean · score on a scale
Change From Baseline in the FACIT-Fatigue Total Score to 9 Months - Interim Analysis
score on a scaleLNP023 200mg b.i.dPlacebo
Change From Baseline in the FACIT-Fatigue Total Score to 9 Months - Interim Analysis0.6 (-0.7 to 1.9)-0.3 (-1.7 to 1.0)
Statistical analysis
  • LNP023 200mg b.i.d vs Placebo · Mixed Models Analysis · p = 0.1498 (1-sided p-value) · Adjusted mean difference: 1.0 · 95% CI -0.8 to 2.8
SecondaryNumber of Participants With Adverse Events in the Main Study Population During the On-treatment Period - Interim Analysis

Number of participants with treatment-emergent Adverse Events, including clinically significant abnormal safety laboratory parameters and vital signs during the on-treatment period. The on-treatment period lasts from the date of first administration of study treatment to 7 days after the date of the last actual administration of any study treatment

Time frame:
Up to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events in the Main Study Population During the On-treatment Period - Interim Analysis
ParticipantsLNP023 200mg b.i.dPlacebo
Adverse Events (AEs)138153
Treatment-related AEs2629
Fatal Serious AEs00
Serious AEs1811
Treatment -related serious AEs50
AEs leading to discontinuation of treatment66
Severe AEs77
SecondaryNumber of Participants With Adverse Events in the SRI Population During the On-treatment Period - Interim Analysis

Number of participants with treatment-emergent Adverse Events, including clinically significant abnormal safety laboratory parameters and vital signs during the on-treatment period. The on-treatment period lasts from the date of first administration of study treatment to 7 days after the date of the last actual administration of any study treatment

Time frame:
Up to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events in the SRI Population During the On-treatment Period - Interim Analysis
ParticipantsLNP023 200mg b.i.dPlacebo
Adverse Events (AEs)1111
Treatment-related AEs21
Fatal Serious AEs00
Serious AEs22
Treatment-related Serious AEs00
AEs leading to discontinuation of treatment11
Severe AEs32
SecondaryRatio to Baseline in UPCR at 9 Months - Final Analysis

Evaluated at final analysis - Ratio to baseline in Urine Protein to Creatinine Ratio (UPCR), sampled from 24h urine collection, at 9 months. Ratio being: UPCR at 9 months in g/g divided by UPCR at Baseline in g/g. Lower values correspond to better outcomes. In line with the testing strategy, this endpoint was not tested at the final analysis.

Time frame:
Baseline and 9 months
Reported as:
Geometric mean · ratio
Ratio to Baseline in UPCR at 9 Months - Final Analysis
ratioLNP023 200mg b.i.dPlacebo
Ratio to Baseline in UPCR at 9 Months - Final Analysis0.559 (0.514 to 0.607)0.918 (0.843 to 0.999)
Statistical analysis
  • LNP023 200mg b.i.d vs Placebo · Geometric mean ratio: 0.609 · 95% CI 0.54 to 0.685
SecondaryProportion of Participants Reaching Proteinuria < 1 g/g of UPCR 24h at 9 Months - Final Analysis

Evaluated at final analysis - Proportion of participants reaching proteinuria \< 1 g/g of Urine Protein-To-Creatinine Ratio (UPCR) 24h at 9 months, without receiving Corticosteroids/Immunosuppressant (CS/IS) or other newly approved drugs or initiating new background therapy for treatment of IgAN or initiating Kidney Replacement Therapy (KRT). Marginal proportion can be interpreted as the population average probability of being a responder in each treatment group.

Time frame:
Baseline and 9 months
Reported as:
Number · Marginal proportion of participants
Proportion of Participants Reaching Proteinuria < 1 g/g of UPCR 24h at 9 Months - Final Analysis
Marginal proportion of participantsLNP023 200mg b.i.dPlacebo
Proportion of Participants Reaching Proteinuria < 1 g/g of UPCR 24h at 9 Months - Final Analysis0.439 (0.380 to 0.498)0.175 (0.127 to 0.224)
Statistical analysis
  • LNP023 200mg b.i.d vs Placebo · Regression, Logistic · p = <0.0001 (Multiplicity adjusted 1-sided p-value) · Odds ratio (or): 4.445 · 95% CI 2.787 to 7.092
  • LNP023 200mg b.i.d vs Placebo · Diff. in marginal proportions: 0.264 · 95% CI 0.187 to 0.340
SecondaryTime to First Occurrence of Composite Kidney Failure Endpoint Event - Final Analysis

Evaluated at final analysis - Time to first occurrence of composite kidney failure endpoint, defined as a sustained decline in the eGFR of at least 30% from baseline for at least 4 weeks, a sustained eGFR of less than 15 mL/min/1.73m2 for at least 4 weeks, initiation of maintenance dialysis (defined as dialysis for a period of ≥4 weeks) or death from kidney failure. For clarity: Please note that the number of patients with a composite kidney failure endpoint event is presented with statistical analysis of the time to composite kidney failure endpoint event.

Time frame:
Up to 24 months
Reported as:
Count of participants · Participants
Time to First Occurrence of Composite Kidney Failure Endpoint Event - Final Analysis
ParticipantsLNP023 200mg b.i.dPlacebo
Time to First Occurrence of Composite Kidney Failure Endpoint Event - Final Analysis5180
Statistical analysis
  • LNP023 200mg b.i.d vs Placebo · Stratified Cox model · p = 0.0015 (Multiplicity adjusted 1-sided p-value) · Hazard ratio (hr): 0.57 · 95% CI 0.40 to 0.81
SecondaryChange From Baseline in the FACIT-Fatigue Total Score to 9 Months - Final Analysis

Functional Assessment Of Chronic Illness Therapy (FACIT)-Fatigue scale (version 4), is a 13-item questionnaire that assesses patient-perceived tiredness, weakness and difficulty conducting activities due to fatigue. The purpose of FACIT-Fatigue in this study was to assess the experience and impact of fatigue on participants with IgAN. Score ranges from 0 to 52, with higher scores indicating less fatigue.

Time frame:
Baseline and Month 9
Reported as:
Mean · score on a scale
Change From Baseline in the FACIT-Fatigue Total Score to 9 Months - Final Analysis
score on a scaleLNP023 200mg b.i.dPlacebo
Change From Baseline in the FACIT-Fatigue Total Score to 9 Months - Final Analysis1.069 (0.226 to 1.912)0.310 (-0.535 to 1.156)
Statistical analysis
  • LNP023 200mg b.i.d vs Placebo · Mixed Models Analysis · p = 0.1062 (Multiplicity adjusted 1 sided p-value) · Adjusted mean difference: 0.759 · 95% CI -0.434 to 1.951
SecondaryNumber of Participants With Adverse Events in the Main Study Population During the On-treatment Period - Final Analysis

Number of participants with treatment-emergent Adverse Events, including clinically significant abnormal safety laboratory parameters and vital signs during the on-treatment period. The on-treatment period lasts from the date of first administration of study treatment to 7 days after the date of the last actual administration of any study treatment

Time frame:
Up to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events in the Main Study Population During the On-treatment Period - Final Analysis
ParticipantsLNP023 200mg b.i.dPlacebo
Adverse Events (AEs)207213
Treatment-related AEs4849
Fatal Serious AEs00
Serious AEs2928
Treatment-related serious AEs92
AEs leading to discontinuation of treatment1111
Treatment-related AEs leading to discontinuation of treatment50
Severe AEs1518
Treatment-related severe AEs42
SecondaryNumber of Participants With Adverse Events in the SRI Population During the On-treatment Period- Final Analysis

Number of participants with treatment-emergent Adverse Events, including clinically significant abnormal safety laboratory parameters and vital signs during the on-treatment period. The on-treatment period lasts from the date of first administration of study treatment to 7 days after the date of the last actual administration of any study treatment

Time frame:
Up to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events in the SRI Population During the On-treatment Period- Final Analysis
ParticipantsLNP023 200mg b.i.dPlacebo
Adverse Events (AEs)1817
Treatment-related AEs32
Fatal Serious AEs00
Serious AEs42
Treatment-related Serious AEs10
AEs leading to discontinuation of treatment11
Treatment-related AEs leading to discontinuation of treatment00
Severe AEs32
Treatment-related Severe AEs10

Adverse events

Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 25 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
On-trt LNP023 200mg b.i.d. Main0/238 (0%)29/238 (12.2%)168/238 (70.6%)
On-trt Placebo Main0/239 (0%)28/239 (11.7%)173/239 (72.4%)
On-trt All Participants Main0/477 (0%)57/477 (11.9%)341/477 (71.5%)
On-trt LNP023 200mg b.i.d. SRI0/21 (0%)4/21 (19%)15/21 (71.4%)
On-trt Placebo SRI0/19 (0%)2/19 (10.5%)17/19 (89.5%)
On-trt All Participants SRI0/40 (0%)6/40 (15%)32/40 (80%)
Post-trt LNP023 200mg b.i.d. Main0/238 (0%)9/238 (3.8%)16/238 (6.7%)
Post-trt Placebo Main0/239 (0%)9/239 (3.8%)29/239 (12.1%)
Post-trt All Participants Main0/477 (0%)18/477 (3.8%)45/477 (9.4%)
Post-trt LNP023 200mg b.i.d. SRI0/21 (0%)2/21 (9.5%)4/21 (19%)
Post-trt Placebo SRI0/19 (0%)3/19 (15.8%)5/19 (26.3%)
Post-trt All Participants SRI0/40 (0%)5/40 (12.5%)9/40 (22.5%)
Most frequent serious events
Showing 10 of 76
Most frequent serious events
EventOn-trt LNP023 200mg b.i.d. MainOn-trt Placebo MainOn-trt All Participants MainOn-trt LNP023 200mg b.i.d. SRIOn-trt Placebo SRIOn-trt All Participants SRIPost-trt LNP023 200mg b.i.d. MainPost-trt Placebo MainPost-trt All Participants MainPost-trt LNP023 200mg b.i.d. SRIPost-trt Placebo SRIPost-trt All Participants SRI
COVID-19Infections and infestations1/2380/2391/4770/210/190/400/2380/2390/4770/211/191/40
International normalised ratio increasedInvestigations0/2380/2390/4770/211/191/400/2380/2390/4770/210/190/40
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2380/2390/4770/211/191/400/2380/2390/4770/210/190/40
Acute kidney injuryRenal and urinary disorders4/2382/2396/4770/211/191/401/2381/2392/4770/210/190/40
Chronic kidney diseaseRenal and urinary disorders0/2381/2391/4770/211/191/400/2383/2393/4771/210/191/40
End stage renal diseaseRenal and urinary disorders0/2380/2390/4770/210/190/400/2380/2390/4770/211/191/40
Renal failureRenal and urinary disorders0/2380/2390/4771/210/191/400/2382/2392/4770/211/191/40
HypertensionVascular disorders0/2380/2390/4770/210/190/400/2380/2390/4770/211/191/40
PneumoniaInfections and infestations4/2381/2395/4771/210/191/400/2380/2390/4770/210/190/40
Pneumonia bacterialInfections and infestations1/2381/2392/4771/210/191/400/2380/2390/4770/210/190/40
Most frequent other events
Showing 10 of 78
Most frequent other events
EventOn-trt LNP023 200mg b.i.d. MainOn-trt Placebo MainOn-trt All Participants MainOn-trt LNP023 200mg b.i.d. SRIOn-trt Placebo SRIOn-trt All Participants SRIPost-trt LNP023 200mg b.i.d. MainPost-trt Placebo MainPost-trt All Participants MainPost-trt LNP023 200mg b.i.d. SRIPost-trt Placebo SRIPost-trt All Participants SRI
COVID-19Infections and infestations49/23847/23996/4774/216/1910/400/2385/2395/4771/210/191/40
HyperkalaemiaMetabolism and nutrition disorders10/23818/23928/4772/215/197/401/2383/2394/4771/211/192/40
Upper respiratory tract infectionInfections and infestations38/23837/23975/4770/210/190/401/2385/2396/4770/210/190/40
HypertensionVascular disorders6/23824/23930/4772/213/195/401/2380/2391/4772/210/192/40
InfluenzaInfections and infestations11/23810/23921/4773/211/194/400/2381/2391/4770/210/190/40
HyperlipidaemiaMetabolism and nutrition disorders13/23816/23929/4773/210/193/400/2380/2390/4770/210/190/40
NasopharyngitisInfections and infestations24/23829/23953/4771/210/191/402/2382/2394/4771/210/191/40
DiarrhoeaGastrointestinal disorders14/23813/23927/4772/211/193/400/2382/2392/4770/212/192/40
Chest painGeneral disorders and administration site conditions4/2385/2399/4770/212/192/401/2380/2391/4770/210/190/40
Urinary tract infectionInfections and infestations6/23811/23917/4771/210/191/400/2380/2390/4770/212/192/40

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)LNP023 200mg b.i.dPlaceboTotal
<=18 years000
Between 18 and 65 years254248502
>=65 years51015
Age, Continuous
Age, Continuous(years)LNP023 200mg b.i.dPlaceboTotal
Mean40.0 ± 11.5239.6 ± 12.4839.8 ± 12.00
Sex: Female, Male
Sex: Female, Male(Participants)LNP023 200mg b.i.dPlaceboTotal
Female111126237
Male148132280
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LNP023 200mg b.i.dPlaceboTotal
Race — White127125252
Race — Black/African American044
Race — Asian129126255
Race — Native Hawaiian or Other Pacific Islander112
Race — American Indian or Alaska Native224
08

Study locations

177 sites
  • AZ Kidney Dise and Hypertension Ctr
    Glendale, Arizona 85306, United States
  • AKDHC Medical Research ServicesLLC
    Phoenix, Arizona 85016, United States
  • UCLA Medical Center
    Los Angeles, California 90095, United States
  • Kaiser Permanente
    San Diego, California 92111, United States
  • North America Research Institute
    San Dimas, California 91773, United States
  • University of Colorado Anschutz
    Aurora, Colorado 80045, United States
  • Nephrology Associates PA
    Newark, Delaware 19713, United States
  • Boise Kidney and Hypertension
    Boise, Idaho 83706, United States
  • CaRe Research
    Chubbuck, Idaho 83202, United States
  • Nep Assoc of Northern Illinois
    Hinsdale, Illinois 60521, United States
  • Renal Associates of Baton Rouge
    Baton Rouge, Louisiana 70808, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Brigham and Womens Hosp Harvard Med School
    Boston, Massachusetts 02115, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • Clin Rsrch Consult a JCCT Company
    Kansas City, Missouri 64112, United States
  • DaVita Clinical Research
    Las Vegas, Nevada 89146, United States
  • New Jersey Kidney Care
    Jersey City, New Jersey 07305, United States
  • Columbia University Irving Medical
    New York, New York 10032, United States
  • Dallas Renal Group
    Dallas, Texas 75230, United States
  • Prolato Clinical Research Center
    Houston, Texas 77054, United States
  • Univ of Washington Medi Cen
    Seattle, Washington 98104, United States
  • Novartis Investigative Site
    Córdoba, Córdoba Province X5016JDA, Argentina
  • Novartis Investigative Site
    Córdoba, Córdoba Province X5016KEH, Argentina
  • Novartis Investigative Site
    CABA, C1181ACH, Argentina
  • Novartis Investigative Site
    CABA, C1426ABP, Argentina
  • Novartis Investigative Site
    Santa Fe, S3000EPV, Argentina
  • Novartis Investigative Site
    Westmead, New South Wales 2145, Australia
  • Novartis Investigative Site
    Woolloongabba, Queensland 4102, Australia
  • Novartis Investigative Site
    Adelaide, South Australia 5000, Australia
  • Novartis Investigative Site
    Parkville, Victoria 3065, Australia
  • Novartis Investigative Site
    St Albans, Victoria 3021, Australia
  • Novartis Investigative Site
    Roeselare, West Vlaanderen 8800, Belgium
  • Novartis Investigative Site
    Edegem, 2650, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Belo Horizonte, Minas Gerais 30150-221, Brazil
  • Novartis Investigative Site
    Curitiba, Paraná 80440-020, Brazil
  • Novartis Investigative Site
    Porto Alegre, Rio Grande do Sul 90035-074, Brazil
  • Novartis Investigative Site
    São José do Rio Preto, São Paulo 15090 000, Brazil
  • Novartis Investigative Site
    São Paulo, São Paulo 04038-002, Brazil
  • Novartis Investigative Site
    São Paulo, São Paulo 05403-000, Brazil
  • Novartis Investigative Site
    Oshawa, Ontario L1G 2B9, Canada
  • Novartis Investigative Site
    Temuco, 4781151, Chile
  • Novartis Investigative Site
    Beijing, Beijing Municipality 100013, China
  • Novartis Investigative Site
    Beijing, Beijing Municipality 102218, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510080, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510630, China
  • Novartis Investigative Site
    Shenzhen, Guangdong 518000, China
  • Novartis Investigative Site
    Luoyang, Henan 471003, China
  • Novartis Investigative Site
    Zhengzhou, Henan 450003, China
  • Novartis Investigative Site
    Changsha, Hunan 410011, China
  • Novartis Investigative Site
    Changchun, Jilin 130041, China
  • Novartis Investigative Site
    Yinchuan, Ningxia 750004, China
  • Novartis Investigative Site
    Taiyuan, Shanxi 030001, China
  • Novartis Investigative Site
    Xian, Shanxi 710061, China
  • Novartis Investigative Site
    Ürümqi, Xinjiang 830001, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310003, China
  • Novartis Investigative Site
    Ningbo, Zhejiang 315016, China
  • Novartis Investigative Site
    Wenzhou, Zhejiang 325000, China
  • Novartis Investigative Site
    Beijing, 100029, China
  • Novartis Investigative Site
    Beijing, 100034, China
  • Novartis Investigative Site
    Guangzhou, 510080, China
  • Novartis Investigative Site
    Ningbo, 315010, China
  • Novartis Investigative Site
    Qingdao, 266000, China
  • Novartis Investigative Site
    Shanghai, 200025, China
  • Novartis Investigative Site
    Shanghai, 200040, China
  • Novartis Investigative Site
    Shenzhen, 518036, China
  • Novartis Investigative Site
    Medellín, Antioquia 050001, Colombia
  • Novartis Investigative Site
    Barranquilla, Atlántico 080020, Colombia
  • Novartis Investigative Site
    Prague, 128 08, Czechia
  • Novartis Investigative Site
    Aalborg, 9000, Denmark
  • Novartis Investigative Site
    Arhus N, 8200, Denmark
  • Novartis Investigative Site
    Copenhagen, 2100, Denmark
  • Novartis Investigative Site
    Odense C, 5000, Denmark
  • Novartis Investigative Site
    Marseille, 13005, France
  • Novartis Investigative Site
    Montpellier, 34295, France
  • Novartis Investigative Site
    Paris, 75015, France
  • Novartis Investigative Site
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
  • Novartis Investigative Site
    Stuttgart, Baden-Wurttemberg 70376, Germany
  • Novartis Investigative Site
    Göttingen, Lower Saxony 37075, Germany
  • Novartis Investigative Site
    Dresden, Saxony 01307, Germany
  • Novartis Investigative Site
    Aachen, 52074, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Hanover, 30625, Germany
  • Novartis Investigative Site
    Kiel, 24105, Germany
  • Novartis Investigative Site
    Magdeburg, 39120, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Tübingen, 72076, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
  • Novartis Investigative Site
    Pécs, Baranya 7623, Hungary
  • Novartis Investigative Site
    Debrecen, Hajdu Bihar Megye 4032, Hungary
  • Novartis Investigative Site
    Szeged, 6725, Hungary
  • Novartis Investigative Site
    Bangalore, Karnataka 560004, India
  • Novartis Investigative Site
    New Delhi, National Capital Territory of Delhi 110017, India
  • Novartis Investigative Site
    New Delhi, National Capital Territory of Delhi 110029, India
  • Novartis Investigative Site
    Hyderabad, Telangana 500082, India
  • Novartis Investigative Site
    Ashkelon, 7830604, Israel
  • Novartis Investigative Site
    Jerusalem, 9112001, Israel
  • Novartis Investigative Site
    Petah Tikva, 4941492, Israel

Showing the first 100 of 177 sites across 35 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Rovin BH, Trimarchi H, Maes B, Perkovic V, Kashihara N, Zhang H, Barratt J, Cheng H, Lee H, Lee SH, Lim SK, Raju SB, Satirapoj B, Seyahi N, Tian YC, Wu CH, Xiong ZY, Xue H, Yee SY, Petrovic-Bulatovic K, Attari Z, Butylin D, Jacinto-Sanders S, Pletscher M, Magirr A, Renfurm R, Hach T, Rizk DV. Long-term efficacy and safety for the complement factor B inhibitor iptacopan in IgA nephropathy. Kidney Int. 2026 Oct 22:S0085-2538(26)00826-4. doi: 10.1016/j.kint.2026.09.017. Online ahead of print. PubMed 42909451 ↗
  • Barratt J, Eren N, Kashihara N, Maes B, Rizk DV, Rovin B, Trimarchi H, Zhang H, Wang W, Kocyigit I, Hao C, Tesar V, Turgutalp K, Yang L, Xing G, Duro Garcia V, Han SH, Lu W, Pisani A, Weinmann-Menke J, Eitner F, Guerard N, Butylin D, Monaco L, Scosyrev E, Magirr A, Renfurm R, Hach T, Perkovic V; APPLAUSE-IgAN Study Group. Iptacopan in IgA Nephropathy - Final 24-Month Data. N Engl J Med. 2026 Jul 30;395(5):465-477. doi: 10.1056/NEJMoa2600743. Epub 2026 Mar 29. PubMed 41910396 ↗
  • Howie AJ, Lalayiannis AD. The Oxford Classification Should Remain the Gold Standard for Classification of IgA Nephropathy: CON. Kidney360. 2026 Oct 1;7(10):2382-2384. doi: 10.34067/KID.0000001083. Epub 2026 Feb 9. No abstract available. PubMed 41661687 ↗
  • Perkovic V, Barratt J, Rovin B, Kashihara N, Maes B, Zhang H, Trimarchi H, Kollins D, Papachristofi O, Jacinto-Sanders S, Merkel T, Guerard N, Renfurm R, Hach T, Rizk DV; APPLAUSE-IgAN Investigators. Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy. N Engl J Med. 2025 Feb 6;392(6):531-543. doi: 10.1056/NEJMoa2410316. Epub 2024 Oct 25. PubMed 39453772 ↗
  • Tunnicliffe DJ, Reid S, Craig JC, Samuels JA, Molony DA, Strippoli GF. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev. 2024 Feb 1;2(2):CD003962. doi: 10.1002/14651858.CD003962.pub3. PubMed 38299639 ↗
  • Zhang H, Rizk DV, Perkovic V, Maes B, Kashihara N, Rovin B, Trimarchi H, Sprangers B, Meier M, Kollins D, Papachristofi O, Milojevic J, Junge G, Nidamarthy PK, Charney A, Barratt J. Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. Kidney Int. 2024 Jan;105(1):189-199. doi: 10.1016/j.kint.2023.09.027. Epub 2023 Oct 31. PubMed 37914086 ↗
  • El Karoui K, Fervenza FC, De Vriese AS. Treatment of IgA Nephropathy: A Rapidly Evolving Field. J Am Soc Nephrol. 2024 Jan 1;35(1):103-116. doi: 10.1681/ASN.0000000000000242. Epub 2023 Sep 29. PubMed 37772889 ↗
  • Reich HN, Floege J. How I Treat IgA Nephropathy. Clin J Am Soc Nephrol. 2022 Aug;17(8):1243-1246. doi: 10.2215/CJN.02710322. Epub 2022 Jun 8. No abstract available. PubMed 35675911 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Sep 2025, 55 months.

Results were first posted in Nov 2026, 1 year 1 month after primary completion.

Of 26 phase 3 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 70. This study's 55 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2020
First posted
Oct 8, 2020
StartActual
Jan 25, 2021
Primary completionActual
Sep 19, 2025
CompletionActual
Sep 19, 2025
Results first posted
Nov 4, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 4, 2026
Sites
6 sites added, 6 sites removed
Show 6 added (1 Belgium, 1 Brazil, 1 Japan, 1 Mexico, 1 Slovakia, 1 South Korea)
  • Novartis Investigative Site · Roeselare, Belgium
  • Novartis Investigative Site · São José do Rio Preto, Brazil
  • Novartis Investigative Site · Yokohama, Japan
  • Novartis Investigative Site · Benito Juárez, Mexico
  • Novartis Investigative Site · Košice, Slovakia
  • Novartis Investigative Site · Seoul, South Korea
Show 6 removed
  • Novartis Investigative Site · Roeselare, Belgium
  • Novartis Investigative Site · Sao Jose Rio Preto, Brazil
  • Novartis Investigative Site · Yokohama, Japan
  • Novartis Investigative Site · Mexico City, Mexico
  • Novartis Investigative Site · Košice, Slovakia
  • Novartis Investigative Site · Seoul, South Korea
Nov 4, 2026
Enrollment
518→517
Nov 4, 2026
Eligibility
1 exclusion criterion removed
What changed in the criteria
Exclusion criteria
  • RemovedOther protocol-defined inclusion/exclusion criteria may apply.
Nov 4, 2026
Primary outcomes
2 added, 2 removed
What changed in the outcomes
  • AddedRatio to Baseline in UPCR at 9 Months - Interim AnalysisTime frame: Baseline and 9 months
  • AddedAnnualized Total eGFR Slope Estimated Over 24 Months - Final AnalysisTime frame: 24 months
  • RemovedRatio to baseline in Urine Protein to Creatinine Ratio (sampled from 24h urine collection) at 9 monthsTime frame: Baseline and 9 months
  • RemovedAnnualized total estimated Glomerular Filtration Rate (eGFR) slope over 24 months).Time frame: Baseline and 24 months
Nov 4, 2026
Documents
Publications
2 publications citing this study linked from PubMed, e.g. PubMed 42909451 ↗
Nov 4, 2026
Secondary outcomes
3 edited, 9 added, 5 removed
What changed in the outcomes
  • EditedChange from baselineFrom Baseline in estimated glomerular filtration rateeGFR at 9 monthsMonths - Interim AnalysisTime frame: Baseline and 9 months
  • EditedAnnualized totalTotal eGFR Slope Estimated Glomerular Filtration Rate slope estimated overOver 12 monthsMonths - Interim AnalysisTime frame: Baseline and 12 months → 12 months
  • EditedTime from randomization to first occurrenceFirst Occurrence of composite kidney failure endpoint eventComposite Kidney Failure Endpoint Event - Final AnalysisTime frame: Up to 24 months
  • AddedProportion of Participants Reaching Proteinuria < 1 g/g of UPCR 24h at 9 Months - Interim AnalysisTime frame: Baseline and 9 months
  • AddedChange From Baseline in the FACIT-Fatigue Total Score to 9 Months - Interim AnalysisTime frame: Baseline and 9 months
  • AddedNumber of Participants With Adverse Events in the Main Study Population During the On-treatment Period - Interim AnalysisTime frame: Up to 24 months
  • AddedNumber of Participants With Adverse Events in the SRI Population During the On-treatment Period - Interim AnalysisTime frame: Up to 24 months
  • AddedRatio to Baseline in UPCR at 9 Months - Final AnalysisTime frame: Baseline and 9 months
  • AddedProportion of Participants Reaching Proteinuria < 1 g/g of UPCR 24h at 9 Months - Final AnalysisTime frame: Baseline and 9 months
  • AddedChange From Baseline in the FACIT-Fatigue Total Score to 9 Months - Final AnalysisTime frame: Baseline and Month 9
  • AddedNumber of Participants With Adverse Events in the Main Study Population During the On-treatment Period - Final AnalysisTime frame: Up to 24 months
  • AddedNumber of Participants With Adverse Events in the SRI Population During the On-treatment Period- Final AnalysisTime frame: Up to 24 months
  • RemovedProportion of participants reaching Urine Protein To Creatinine Ratio <1g/g without receiving Corticosteroids/Immunosuppressant or other newly approved drugs or initiating new background therapy for treatment of IgAN or Kidney Replacement Therapy (KRT)Time frame: Baseline and 9 months
  • RemovedChange from baseline to 9 months in the fatigue scale measured by the Functional Assessment Of Chronic Illness Therapy-Fatigue questionnaireTime frame: Baseline and 9 months
  • RemovedRatio to baseline in Urine Protein-To-Creatinine Ratio (sampled from 24h urine collection) at 9 monthsTime frame: Baseline and 9 months
  • RemovedProportion of participants reaching Urine Protein-To-Creatinine Ratio <1g/g without receiving Corticosteroids/Immunosuppressant Therapy or other newly approved drugs or initiating new background therapy for treatment of IgAN or initiating KRTTime frame: Baseline and 9 months
  • RemovedChange from baseline to 9 months in the fatigue scale measured by the Functional Assessment Of Chronic Illness Therapy-Fatigue questionnaire.Time frame: Baseline and 9 months
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Results posted
    Publications 2 publications citing this study linked from PubMed, e.g. PubMed 42909451 ↗
    6 sites added, 6 sites removed
    Show 6 added (1 Belgium, 1 Brazil, 1 Japan, 1 Mexico, 1 Slovakia, 1 South Korea)
    • Novartis Investigative Site · Roeselare, Belgium
    • Novartis Investigative Site · São José do Rio Preto, Brazil
    • Novartis Investigative Site · Yokohama, Japan
    • Novartis Investigative Site · Benito Juárez, Mexico
    • Novartis Investigative Site · Košice, Slovakia
    • Novartis Investigative Site · Seoul, South Korea
    Show 6 removed
    • Novartis Investigative Site · Roeselare, Belgium
    • Novartis Investigative Site · Sao Jose Rio Preto, Brazil
    • Novartis Investigative Site · Yokohama, Japan
    • Novartis Investigative Site · Mexico City, Mexico
    • Novartis Investigative Site · Košice, Slovakia
    • Novartis Investigative Site · Seoul, South Korea
    Enrollment 518→517
    Eligibility 1 exclusion criterion removed
    What changed in the criteria
    Exclusion criteria
    • RemovedOther protocol-defined inclusion/exclusion criteria may apply.
    Primary outcomes 2 added, 2 removed
    What changed in the outcomes
    • AddedRatio to Baseline in UPCR at 9 Months - Interim AnalysisTime frame: Baseline and 9 months
    • AddedAnnualized Total eGFR Slope Estimated Over 24 Months - Final AnalysisTime frame: 24 months
    • RemovedRatio to baseline in Urine Protein to Creatinine Ratio (sampled from 24h urine collection) at 9 monthsTime frame: Baseline and 9 months
    • RemovedAnnualized total estimated Glomerular Filtration Rate (eGFR) slope over 24 months).Time frame: Baseline and 24 months
    Secondary outcomes 3 edited, 9 added, 5 removed
    What changed in the outcomes
    • EditedChange from baselineFrom Baseline in estimated glomerular filtration rateeGFR at 9 monthsMonths - Interim AnalysisTime frame: Baseline and 9 months
    • EditedAnnualized totalTotal eGFR Slope Estimated Glomerular Filtration Rate slope estimated overOver 12 monthsMonths - Interim AnalysisTime frame: Baseline and 12 months → 12 months
    • EditedTime from randomization to first occurrenceFirst Occurrence of composite kidney failure endpoint eventComposite Kidney Failure Endpoint Event - Final AnalysisTime frame: Up to 24 months
    • AddedProportion of Participants Reaching Proteinuria < 1 g/g of UPCR 24h at 9 Months - Interim AnalysisTime frame: Baseline and 9 months
    • AddedChange From Baseline in the FACIT-Fatigue Total Score to 9 Months - Interim AnalysisTime frame: Baseline and 9 months
    • AddedNumber of Participants With Adverse Events in the Main Study Population During the On-treatment Period - Interim AnalysisTime frame: Up to 24 months
    • AddedNumber of Participants With Adverse Events in the SRI Population During the On-treatment Period - Interim AnalysisTime frame: Up to 24 months
    • AddedRatio to Baseline in UPCR at 9 Months - Final AnalysisTime frame: Baseline and 9 months
    • AddedProportion of Participants Reaching Proteinuria < 1 g/g of UPCR 24h at 9 Months - Final AnalysisTime frame: Baseline and 9 months
    • AddedChange From Baseline in the FACIT-Fatigue Total Score to 9 Months - Final AnalysisTime frame: Baseline and Month 9
    • AddedNumber of Participants With Adverse Events in the Main Study Population During the On-treatment Period - Final AnalysisTime frame: Up to 24 months
    • AddedNumber of Participants With Adverse Events in the SRI Population During the On-treatment Period- Final AnalysisTime frame: Up to 24 months
    • RemovedProportion of participants reaching Urine Protein To Creatinine Ratio <1g/g without receiving Corticosteroids/Immunosuppressant or other newly approved drugs or initiating new background therapy for treatment of IgAN or Kidney Replacement Therapy (KRT)Time frame: Baseline and 9 months
    • RemovedChange from baseline to 9 months in the fatigue scale measured by the Functional Assessment Of Chronic Illness Therapy-Fatigue questionnaireTime frame: Baseline and 9 months
    • RemovedRatio to baseline in Urine Protein-To-Creatinine Ratio (sampled from 24h urine collection) at 9 monthsTime frame: Baseline and 9 months
    • RemovedProportion of participants reaching Urine Protein-To-Creatinine Ratio <1g/g without receiving Corticosteroids/Immunosuppressant Therapy or other newly approved drugs or initiating new background therapy for treatment of IgAN or initiating KRTTime frame: Baseline and 9 months
    • RemovedChange from baseline to 9 months in the fatigue scale measured by the Functional Assessment Of Chronic Illness Therapy-Fatigue questionnaire.Time frame: Baseline and 9 months
    + 4 other changes: identifiers, verification date, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04578834
Responsible party
Sponsor
First posted
Oct 8, 2020
Start date
Jan 25, 2021
Primary completion
Sep 19, 2025
Completion
Sep 19, 2025
Results posted
Nov 4, 2026
Last update
Nov 4, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iptacopan

Start the discussion